By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Austrian biomarker firm Biocrates and Canadian firm Chenomx have signed a co-marketing pact, under which the firms will combine their technologies to generate metabolic profiling tools for monitoring the effects of disease, nutrition, toxins, environment, or drugs on an organism.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.